LONDON (ShareCast) - (Sharecast News) - Neuroscience imaging firm Ixico has signed a contract with a new US-based client to provide imaging services for a Phase 2 Huntington's Disease clinical trial.
Ixico said on Tuesday that the contract value, which will be delivered over approximately two and a half years, was worth more than £500,000 to the company.

The AIM-listed firm added that the contract award reinforced its "sustained positive commercial momentum" and aligns with its strategic pillars to drive expansion and growth.

Chief executie Bram Goorden said: "We are delighted to announce our involvement in this Phase 2 clinical trial, which aims to address the urgent need for effective treatments for Huntington's disease.

"This contract further demonstrates Ixico's expertise in supporting neurodegenerative disease trials, reinforcing our role as a trusted partner for sponsors."

As of 1045 GMT, Ixico shares were up 0.093% at 10.76p.







Reporting by Iain Gilbert at Sharecast.com

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE